Author

S. Bajoria

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

D. B. Volkin· 3 shared H. Kleanthous· 3 shared K. Kaur· 3 shared S. B. Joshi· 3 shared C. A. Naranjo· 2 shared J. C. Love· 2 shared N. C. Dalvie· 2 shared O. S. Kumru· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

D. B. Volkin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor binding domain (RBD)

O. S. Kumru, S. Bajoria, K. Kaur, J. M. Hickey, G. Van Slyke, J. Doering, K. Berman, C. Richardson, H. Lien, H. Kleanthous, N. J. Mantis, S. B. Joshi, D. B. Volkin

This paper evaluates the stability and immunogenicity of a SARS-CoV-2 RBD VLP vaccine candidate formulated with different adjuvants and finds that AP and AH adjuvants provide comparable immunogenicity to AV, with AP showing higher neutralizing titers.

bioRxiv · Jul 10, 2023Immunology

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants

S. A. Rodriguez-Aponte, N. C. Dalvie, T. Y. Wong, R. S. Johnston, C. A. Naranjo, S. Bajoria, O. S. Kumru, K. Kaur, B. P. Russ, K. S. Lee, H. A. Cyphert, M. Barbier, H. D. Rao, M. P. Rajurkar, R. R. Lothe, , J. C. Love

bioRxiv · Sep 14, 2022Bioengineering

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology